Physician profile
Alejandro Zapata
NPI 1467461855
$8,878.91
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $1,450 · 2021: $2,648 · 2022: $2,241 · 2023: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,466.72 | 2019-2023 | Rexulti, Abilify Mycite, Abilify Maintena |
| Alkermes, INC. | $1,358.95 | 2019-2023 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $876.58 | 2019-2023 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $873.44 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $767.88 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $581.22 | 2019-2023 | Ingrezza |
| Abbvie INC. | $549.36 | 2021-2023 | Vraylar |
| Lundbeck LLC | $522.70 | 2019-2023 | Rexulti |
| Allergan, INC. | $355.30 | 2019-2021 | |
| Validus Pharmaceuticals LLC | $245.14 | 2019-2023 | Equetro |
| Avanir Pharmaceuticals, INC. | $244.91 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $232.45 | 2019-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $163.43 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.79 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $116.03 | 2019-2023 | Austedo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $71.17 | 2023 | Auvelity |
| Corium, LLC | $59.39 | 2022-2023 | Azstarys |
| Shire North American Group INC | $53.64 | 2019 | |
| Supernus Pharmaceuticals, INC. | $43.54 | 2021-2022 | |
| Bausch Health US, LLC | $38.63 | 2019-2020 | |
| Indivior INC. | $24.38 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $21.61 | 2022 | |
| Adlon Therapeutics L.P. | $19.08 | 2021 | |
| Eisai INC. | $17.56 | 2020 | |
| Tris Pharma INC | $15.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Zapata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.